Introduction
Techniques have been developed to analyse baseline variables, particularly the mean (SD) of continuous variables, and these have helped to identify fabricated data in randomised, controlled trials by Fujii et al. [1] . The general principles of these methods have been explained elsewhere [2, 3] . The same approach has been used to investigate trials published by Yuhji Saitoh, a co-author of Dr Fujii, and form a component of the investigation of his work [4] . The technique has recently identified systematic problems with data in 33 randomised trials by Yoshihiro Sato, who is not an anaesthetist [5] .
Fujii features top in a list of biomedical authors with the most retractions, and, for quite separate reasons from those based on statistical data analysis, two other anaesthetists appear in this list: second (Boldt) and fifteenth (Reuben) [6] . Several questions arise. Are trials published by anaesthetists more likely to be retracted than trials from other specialists? Are anaesthetists more likely to generate fabricated data in trials? Would the statistical methods used to discover issues with data published by Fujii and Saitoh [1, 3] also retrospectively find aberrations in baseline data of trials published by authors like Boldt and Reuben?
The purpose of this survey is to assess if: (1) the distribution of baseline means corresponded to the expected distribution and whether discrepancies were shared by leading non-anaesthetic vs. anaesthetic journals; (2) there was a different rate of retraction in leading non-anaesthetic vs. anaesthetic journals; and (3) data corruption was discoverable by the new statistical techniques in those papers/authors that had been retracted. I used the method to detect anomalies in the distributions of baseline variable mean (SD) from randomised, controlled trials published during 15 years in six specialist anaesthetic journals (Anaesthesia, Anesthesia and Analgesia, Anesthesiology, the British Journal of Anaesthesia, the Canadian Journal of Anesthesia and the European Journal of Anaesthesiology) and two general medical journals (Journal of the American Medical Association (JAMA) and New England Journal of Medicine (NEJM)).
Methods
I searched eight journals (to which I had electronic access) for randomised, controlled trials published between January 2000 and December 2015: Anaesthesia; Anesthesia and Analgesia; Anesthesiology; British Journal of Anaesthesia; Canadian Journal of Anesthesia; European Journal of Anaesthesiology (2002-2012); JAMA; and NEJM. I extracted baseline summary data for continuous variables, reported as mean (SD) or mean (SEM). I did not study trials for which participant allocation was not described as random, or trials that did not report baseline continuous variables, or those that reported a different summary measure, such as median (IQR or range). I defined 'baseline' as a variable measured before groups were exposed to the allocated intervention, variables such as age, height, 'baseline' blood pressure or serum sodium concentration. I excluded variables that had been stratified. I recorded whether the allocation sequence had been generated in blocks, permuted or otherwise, which could reduce the distribution of means for time-varying measurements.
The primary outcome was the distribution of p values, calculated for differences between means, for individual variables and when combined within trials. I used three methods to generate p values for individual variables: independent t-test; ANOVA; and Monte Carlo simulations [5] , adjusted for the precision to which mean (SD) were reported. The p value generated by these three methods that was closest to 0. 
Results
I scanned 9673 clinical trials for the random allocation of baseline variables reported as mean (SD or SEM): 4586 were not randomised, controlled trials or did not present unstratified baseline mean (SD or SE) data. I therefore analysed 5087 trials, which included 72,261 means of 29,789 variables. The supplementary appendices list the trials and the results of analyses (Appendix S1) and the data that I analysed (Appendix S2).
The distribution of 72,261 baseline means was largely consistent with random sampling, with 5087 trial p values being contained within the 99% confidence interval of the cumulative uniform distribution, between p values of 0.15 and 0.95 (Fig. 1) . However, there were more trials than expected with baseline means that were similar (near a p value of 0) or dissimilar (near a p value of 1): 794/5087 (15.6%) trial p values were within 0.05 of 0 or 1, that is, 5.6% more than expected or 1 in 18 trials ( Fig. 1 and Tables 1  and 2 ). Consequently, the distribution of trial p values deviated from the expected distribution, p = 1.2 9 10
À7
. Each journal had the same proportion of trials with extreme p values (Fig. 2) . Although the distribution of p values was not the same in all journals, p = 0.007, there were no significant differences when one journal was tested against any other. There was no difference in distributions of baseline variables of 1453 trials published in non-anaesthetic journals and 3634 trials published in anaesthetic journals, p = 0.30 (Fig. 3) .
More baseline variables from 72 retracted trials had very similar means or very dissimilar means than 5015 trials that are not retracted, p = 5.3 9 10 À15 ( Fig. 4 and Table 1 ). The exclusion of retracted trials (from 5087) did not resolve the discrepancies between the observed and expected distribution of baseline 
Table 1
The numbers of randomised, controlled trials analysed from eight journals and the number (proportion) with p values for baseline means within 0.05 of 0 or 1. To assess if it might be possible to use probability to determine which trials and authors to investigate, to correct erroneous data or to retract fabricated data, I applied different investigative probability thresholds. A threshold of 1 in 10,000 (0.5 in 5000) would have captured 8/72 (11%) retracted trials (7 by Yoshitaka Fujii) and 82/5015 (1.6%) trials that have not yet been corrected or retracted. I supplemented this approach by investigating authors of more than one trial for which the probability was, arbitrarily, less than 1 in 100. This identified trials (number) by Yoshitaka Fujii (13), Joachim Boldt (3) and Scott Reuben (2) . I searched through all the trials by first author and corresponding author and identified 21 other authors of more than one trial (65 in total) with a probability less than 1 in 100. A more thorough but laborious method would be to combine the probabilities calculated for all the trials published by individuals. 595, which presented secondary data from a previously published cohort without reference. Eighteen trials in this survey were authored by Yoshitaka Fujii, all of which were retracted for data fabrication, as were eight trials by Scott Reuben. Figure 5 compares the 26 trials retracted for fabrication with the 44 trials that were retracted for inadequate ethical approval or unclear reasons, such as 'misconduct'. The distributions of baseline data were different in the two subgroups, p = 3.3 9 10 À5 , but neither was at all consistent with the expected distribution, p = 1.9 9 10 À5 and p = 2.3 9 10 À5 , respectively. Trials retracted due to unethical practice or ill-defined reasons might therefore also contain corrupt data, due to error or fabrication.
Discussion
I analysed the proximity of means for baseline variables in 5087 randomised, controlled trials. In 15.6% of trials, the probability of a more extreme distribution was 1 in 10. Retracted trials had a higher proportion of p values in the extreme 10% of the expected distribution than trials that have not been retracted (43% vs. 15%). There was evidence that trials retracted for reasons other than data integrity may have contained corrupt and possibly fabricated data. Trials with extreme distributions of means were more likely to contain incorrect or fabricated data than other trials, as has been independently verified.
The discrepancy between the observed distribution and the expected distribution of p values could be because the expected distribution was wrong. I was aware that stratified allocation could make group means more similar, which is why I did not analyse the means of stratified variables. However, the effect could have 'carried over' into non-stratified variables: for instance, the mean weights of groups might have been made more similar through stratification by sex or height. The excess of dissimilar means would not be explained by this mechanism, although correlations between variables could account for excess trials with p values at either extreme (near 0 or 1). Simulations could generate credible intervals for the contribution of stratification and correlation with extreme p values. Investigators can manipulate the distribution of participants into groups if the allocation sequence is inadequately masked or if the allocation sequence is predictable. The manipulation of participant allocation could result in baseline mean values that are similar or dissimilar, depending upon the motivation and efficacy of the method used to distort random allocation. The 'observed' distribution may have been distorted by my mistakes. It is likely that I incorrectly transcribed some of the 72,261 means, 72,261 standard deviations, 72,261 participant numbers and 72,261 precisions for mean and SD.
Some trials with extreme p values probably contained unintentional typographical errors, such as the description of standard error as standard deviation and vice versa. The more extreme the p value the more likely Figure 5 The expected cumulative uniform distribution ( ) was not followed by the 26 trials retracted for fabrication ( ), p = 1.9 9 10 À5 , composed of trials by Fujii ( ) and Reuben (X); and it was not followed by the 44 trials retracted for other reasons ( ), p = 2.3 9 10 À5 , composed of trials by Boldt ( ) and others ( ). The cumulative distributions of these two categories of retracted articles were different, p = 3.3 9 10
À5
. there is to be an error (mine or the authors'), either unintentional or fabrication. For instance, for 43/5015 unretracted and uncorrected trials, the probability that random allocation would result in the distributions of baseline means was less than 1 in 10 15 (one water drop in 20,000 Olympic-sized swimming pools). In a sample of just over 5000 trials it seems reasonable to conclude that these trials -and others with more likely distributions -almost certainly contain some sort of error. The association of extreme distributions with trial retraction suggests that further investigation of uncorrected unretracted trials and their authors will result in most trials being corrected and some retracted. The evidence for this association in this survey comes mainly from specialist anaesthetic journals. It is unclear whether trials in the anaesthetic journals have been more deserving of retraction, or perhaps there is a deficit of retractions from JAMA and NEJM. In summary, the distribution of means for baseline variables in randomised, controlled trials was inconsistent with random sampling, due to an excess of very similar means and an excess of very dissimilar means. Fraud, unintentional error, correlation, stratified allocation and poor methodology might have contributed to this distortion. The distortion in two non-specialist medical journals was indistinguishable from that found in six specialist anaesthetic journals. Future work might determine whether this finding is general to all randomised, controlled trials. Journal editors could use Table 2 and online Appendix S1 to determine which trials to correct and if necessary retract.
